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The Ubiquitin+Proteasome System (UPS) represents a successful anti-cancer strategy that 
has translated from preclinical studies to clinical development and significantly improved 
the survival of Multiple Myeloma (MM) patients (1). The proteasome is high molecular 
weight structure that contains multiple proteolytic sites and functions as the catalytic core of 
the UPS to degrade Ub~conjugated proteins (2-4). Inhibition of the proteasome’s 
chymotryptic-like peptidase activity blocks the entire UPS and leads to selective tumor cell 
death. Bortezomib is the first proteasome inhibitor used in human clinical trials and 
treatment leads to a reduction in tumor burden in MM patients (5,6). However, cellular 
resistance to proteasome-based therapy generally results and reduces the efficacy. 
Resistance to proteasome inhibitors may result from altered expression of either proteasome 
or non-proteasome encoding genes. SUMOylation is a post-translational modification that 
attaches a Small Ubiquitin-like MOdifier to target proteins and, similar to Ub, may target 
proteins for proteasomal degradation. Gene expression profiling of MM patient samples 
indicated that bortezomib resistance may be achieved through induction of non-proteasome 
components. Importantly, certain effectors of the SUMOylation pathway were induced in 
the samples of MM patients that did not respond to bortezomib. A molecular-based, 
biologically-relevant supervised approach was used to identify a compendium of genes 
within the SUMO+UPS that were induced in MM patients and correlated with a decreased 
response to bortezomib. This molecular approach is relevant to a heterogeneous disease like 
MM where patients with similar clinical and pathologic features have vastly different 
genetic mutations responsible for disease and varying responses to therapies and clinical 
outcomes. The potential role of the SUMOylation pathway is only beginning to emerge, 
however, evidence indicates that SUMOylation is induced in myelomagenesis and also in 
bortezomib-resistant cells. 
An aggresome is a proteinaceous inclusion body that forms when the cellular protein 
degradation machinery is impaired or overwhelmed and leads to an accumulation of 
proteins for disposal (7,8). Aggresome formation is thought to represent a cellular protective 
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response to the presence of abnormal, misfolded or damaged proteins within the cytoplasm 
that cannot be eliminated by the UPS. Aggresomes form adjacent to the microtubule-
organizing center (MTOC) and neighboring the centrosome. The microtubule-based motor 
protein dynein, heat shock proteins and the histone deacetylase 6 (HDAC6) have been 
reported as aggresome components (9). HDAC6 specifically functions as an adaptor protein 
between the dynein motor protein and accumulating polyubiquitinated substrate proteins. 
The protein aggregates that reside in an aggresome are sequestered in a cage that consists 
largely of intermediate filaments. Aggresome formation may serve as an alternative 
mechanism to eliminate the cytotoxic effect of accumulated Ub~protein conjugates. Recent 
evidence indicates that SUMOylation effectors and SUMO-modified proteins are related to 
aggresome formation. Inhibition of SUMOylation could preclude aggresome formation and 
consequently overcome bortezomib resistance.  
 The formation of the aggresome functions as a mechanism not only to sequester potentially 
cytotoxic aggregates but also to serve as a platform for the eventual autophagic clearance of 
these aggregates (10, 11). Autophagy is a catabolic process that involves the degradation of 
the cell's own constituents through the lysosomal machinery (12, 13). It is a tightly-regulated 
process that plays a normal part in cell growth, development, and homeostasis and 
maintains the balance between the synthesis, degradation and subsequent recycling of 
cellular products. It is a major mechanism by which a starving cell reallocates nutrients from 
unnecessary processes to more-essential processes. A variety of autophagic processes exist, 
all having in common the degradation of intracellular components through the lysosome. 
The most well-known mechanism of autophagy involves the formation of a membrane 
around a targeted region of the cell, separating the contents from the rest of the cytoplasm. 
The resultant vesicle then fuses with a lysosome and subsequently degrades the contents. 
Importantly, new evidence indicates upon proteasome inhibition, the accumulated 
Ub~protein conjugates are bound by autophagy cargo receptors for clearance (14, 15). Thus, 
it appears that aggresome formation is a prerequisite for autophagic clearance of 
Ub~protein conjugates (16). In addition, selective autophagy may serve to eliminate these 
aggregates and overcome proteasome inhibition and yield drug resistance. It remains to be 
determined whether SUMOylated proteins are also cleared by autophagic clearance. 
However, inhibition of the SUMOylation pathwya may prevent aggresome formation, 
impede their autophagic clearance of Ub~protein conjugates and overcome bortezomib 
resistance. Future studies will address these questions and may yield new therapeutic 
targets, novel anti-cancer agents and lead to improved strategies for the treatment of MM 
and other malignancies. 
2. Clinical success of proteasome inhibitor-based therapy in multiple 
myeloma 
Multiple myeloma (MM) is a hematologic neoplasm of B-cell origin characterized by the 
clonal proliferation and progressive accumulation of malignant plasma cells within the bone 
marrow. MM accounts for greater than 10% of all hematologic cancers and in spite of 
conventional high-dose chemotherapies, remains uniformly fatal, in part, because of either 
intrinsic (primary) or acquired (secondary) drug resistance. Recent advances in translational 
medicine have led to the development of molecularly-based targeted therapies as well as 
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highly effective synergistic drug combinations that have the potential to achieve a higher 
frequency of durable responses in a greater number of MM patients. Molecular, genomic 
and proteomic studies have further increased understanding of the biology of 
myelomagenesis, provided the basis for better prognostic classification in the context of 
uniform therapies and generated a sound rationale for combining targeted therapies in 
current and emerging clinical development. 
The 26S proteasome is a high-molecular weight, multi-subunit complex that consists of a 20S 
catalytic core and a 19S regulatory particle. Proteasomes are found in eukaryotes, 
archaebacteria and some bacteria. The 20S proteasome functions as the catalytic core of the 
ubiquitin-proteasome system to hydrolyze proteins into short polypeptide and is capable of 
hydrolyzing peptides C-terminal to chymotryptic, tryptic or acidic residues. 20S 
proteasomes are cylindrical structures composed of four stacked rings with each ring 
composed of seven individual subunits. The two inner rings are made of seven ┚ subunits 
that contain the various active sites and the two outer rings are each composed of seven ┙ 
subunits. The two outer rings comprised of α subunits are then bound at either pole by the 
19S regulatory particles. 
Proteasome inhibition is a promising therapeutic strategy for the treatment of an increasing 
number of B cell malignancies, especially MM. Bortezomib is a low molecular weight boron-
based agent that inhibits the chymotryptic-like activity of the proteasome. Inhibition of the 
chymotryptic-like activity inhibits all proteasome activity and acts as a blockade of the 
entire ubiquitin+proteasome pathway. The result is the intracellular accumulation of 
Ub~protein conjugates, activation of cellular stress sensors and eventually cell death. The 
selective cytotoxic effect of proteasome inhibition on tumor cells further validated protein 
degradation as a therapeutic target in oncology and has been translated in the treatment of 
certain malignancies. Bortezomib was US Food and Drug Administration (FDA) approved 
for the treatment of newly diagnosed, relapsed and refractory MM. The introduction of 
bortezomib into the treatment of MM resulted in a paradigm shift and significantly 
improved patient survival. The concurrent targeting of both the tumor cell as well as the 
surrounding bone marrow microenvironment may promote tumor cell death and efficacy. 
The FDA has recently approved a more effective three drug combination of bortezomib, 
lenalidomide and dexamethasone for the treatment of MM that may act on the malignant 
plasma cell and also to counteract the protective effect of the bone marrow milieu.  
Many MM patients, however, exhibit an intrinsic (primary) resistance and do not initially 
respond to bortezomib. Furthermore, in those patients that do respond, clinical efficacy is 
dampened by the inevitable emergence of acquired drug-resistance that eventually develops 
through unidentified mechanisms. While bortezomib has significantly transformed the 
management of MM, the mechanism(s) of action and bases of individual patient 
susceptibility remain unclear. These recent advances in mechanistic understanding and 
treatment modalities have extended median survival to >6 years and 10% of patients now 
survive >10 years. However, the vast majority of MM remains incurable even with these 
strategies.  
Though the catabolism of ubiquitinated substrates has been targeted therapeutically with 
significantly improved prognosis, patient response to bortezomib remains highly variable 
and cannot be predicted accurately. E3 Ub ligases are the specific components of the UPS 
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that recognize substrates for degradation and confer specificity on target selection for the 
UPS. Therefore, the expression of individual E3’s was analyzed using a microarray dataset 
obtained from MM patient tumor samples and found a striking variability in the expression 
level of individual E3 Ub ligases between normal plasma cells and patients MM cells. 
Specifically, RNF4, an E3 specific for poly-sumoylated proteins, was induced in MM 
patients and correlated with decreased patient response to the proteasome inhibitor 
bortezomib. Expression profiling of pretreatment tumor samples obtained from MM 
patients in independent clinical trials were used to generate a signature that correlated 
expression of SUMO+Ub+Proteasome pathway components with clinical outcome to predict 
patient response to bortezomib. 
3. The Ub+Proteasome System (UPS) and the Ub-like SUMOylation pathway 
The UPS regulates numerous critical cellular processes by maintaining the appropriate 
intracellular level of key proteins. Whereas de novo protein synthesis is a comparatively slow 
process, proteins are rapidly degraded at a rate compatible with the control of cell cycle 
transitions and cell death induction. The critical role played by Ub-mediated protein 
turnover in cell cycle regulation makes this process a high-value target for oncogenic 
mutations. SUMO proteins are similar to ubiquitin, and SUMOylation is directed by an 
three-step enzymatic cascade analogous to that involved in ubiquitination. SUMOylation is 
a highly dynamic, reversible, post-translational protein modification, similar to 
ubiquitination that attaches a family of polypeptides to target proteins to modify their 
function, subcellular localization or stability. A role for SUMOylation in the UPS has been 
established since SUMO attachment signals the recruitment of specific E3 Ub ligases to 
target proteins, e.g., PML, PEA, PARP-1 and HIF1-alpha, for ubiquitination and proteasomal 
degradation. Induction of individual SUMOylation and UPS effectors has been 
demonstrated in MM cell lines and patient samples and SUMO pathway induction has been 
correlated with resistance to bortezomib-based therapy. Similarly, proteasome components 
are induced in bortezomib-resistant cells ad ndecrease the toxic accumulation of 
Ub~conjugates. The mechanistic link of SUMOylation to proteasomal resistance is uncertain. 
An important unresolved issue is the clinical significance of sumoylation during 
proteasomal degradation and proteasome inhibitor-based therapy. SUMOylation was 
recently shown to have a role in proteasomal degradation since SUMO-2/3 attachment can 
signal Ub-dependent degradation. Novel RING family Ub ligases, e.g., RNF4, bear SUMO 
interaction motifs and have been implicated in the proteasomal degradation of SUMO-
modified target protein PML. Similarly, the E3 Ub ligase von Hippel–Lindau (VHL) has 
been reported to control the levels of sumoylated HIF-1α while VHL and RNF4 control the 
levels of HIF-2 to indicate that sumoylated HIF-2α is degraded through SUMO-targeted 
ubiquitination. SUMO modification as a signal for degradation is conserved in eukaryotes 
and Ub ligases that specifically recognize SUMO-modified proteins have been discovered 
from yeasts to humans. proteasome components to further link the pathways. Individual 
components of the sumoylation pathway serve as biomarkers to predict clinical response to 
bortezomib and provide evidence for targeting SUMO pathway to improve therapeutic 
outcome in myeloma in general and specifically in combination with proteasome inhibitors. 
SUMO modification as a signal for degradation is conserved in eukaryotes and Ub ligases 
that specifically recognize SUMO-modified proteins have been discovered from yeasts to 
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humans. E3 Ub ligases are engaged in the recognition of biologically relevant proteins that 
are degraded by the proteasome. While proteasome inhibition generates the accumulation of 
Ub~conjugated proteins and ultimately cell death, the selectivity of this process and the role 
of individual E3 ligases has not been previously addressed. We investigated whether UPS 
effectors and specifically, E3 ligases were differentially expressed in MM patients and 
whether expression correlated with resistance to bortezomib-based therapy. Recently, we 
demonstrated that genes encoding SUMOylation pathway effectors were induced during 
myelomagenesis and correlated with decreased patient survival.  
4. Aggresomes and proteasome-based therapy 
Aggresomes are novel cellular structures that employ HDAC6 to sequester and transport 
protein aggregates to the autophagy-lysosome system for efficient disposal. These poorly 
defined structures have been shown to consist of HDAC6, microtubules, heat shock proteins 
and ubiquitin. Aggresome formation is induced by a number of cellular and genotoxic 
stressors, including proteasomal inhibition. These structures may represent a potential 
compensatory mechanism to for cells to eliminate Ub~protein conjugates that accumulate 
upon proteasomal inhibiton. The result may be resistance to proteasome inhibitors and 
promote tumor survival. Similar to Ub, the small Ub-like MOdifier (SUMO) is attached to 
target certain proteins for proteasomal degradation but an association with aggresomes has 
not been established. The proteasome is limited in its capacity to degrade certain proteins, 
such as membrane-associated, oligomeric and protein aggregates. SUMOylation, like 
ubiquitination, may be mechanistically and biologically linked to aggresomes to promote 
the removal of toxic proteins that accumulate upon proteasomal inhibition. SUMOylation 
may also be required for the formation of aggresomes. Genetic or pharmacologic targeting 
of SUMOylation pathway effectors may impair functioning and formation of aggresomes to 
overcome drug resistance and enhance the cytotoxicity of proteasome inhibitors. 
5. Autophagy 
Removal of harmful protein aggregates is mediated by autophagy, a mechanism that 
sequesters cytosolic cargo and delivers it to the lysosome (17-20). Autophagy is of great 
importance for cellular homeostasis and survival, while its deregulation has been linked to 
pathological conditions, e.g., certain neurodegenerative diseases and cancer (21-23). The 
process of autophagy for many years has been thought of as a random degradative process 
to eliminate long-lived cell constituents. However, recent evidence indicates that autophagy 
can be selective and mediated through specialized Ub-binding cargo receptors. 
The involvement of Ub as a specificity factor for selective autophagy has resulted in a rapid 
emergence of studies that have demonstrated active communication between the UPS and 
the aggresome-autophagy-lysosomal system (25). The identification and characterization of 
autophagy receptors, such as p62/SQSTM1, NBR1, p97/ VCP which can simultaneously 
bind both Ub and autophagy-specific Ub-like modifiers, e.g., LC3/GABARAP, and possible 
SUMO has provided a molecular link between the UPS and autophagy (26-28). Since the 
UPS regulates the selective degradation of certain short-lived, mutant and misfolded 
proteins, autophagy may remove not only aggregates which are comprised of long-lived 
proteins but also UPS substrates. Selective autophagy may protect cells from oxidative and 
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genotoxic stresses. In addition, this process may remove Ub~ and SUMO~protein 
conjugates that accumulate upon proteasome inhibition and overcome the cytotoxic effect of 
bortezomib. Induction of selective autophagy may be induced in tumor cells to provide a 
mechanism of cell survival and drug resistance (29, 30). Selective autophagy represents a 
promising new pathway to investigate as means to overcome resistance to proteasome 
inhibitors and further advance the treatment of MM. 
6. Conclusions 
Multiple myeloma accounts for a substantial amount of all hematologic malignancies seen 
worldwide. In the US and Europe, the incidence of MM exceeds 40,000 cases annual. MM 
has assumed a position of prominence as a model system for preclinical studies, drug 
development and clinical trials. Unlike other malignancies, in which surgery and radiation 
are important treatment modalities, MM is nearly exclusively treated with stem cell 
transplantation (SCT) or synergistic chemotherapeutic combinations. SCT has produced 
statistically significant survival benefit for MM patients. However, a number of MM patients 
are not eligible for SCT either because of age, toxicities and many patients can relapse. 
Novel therapeutic agents such as the immunomodulatory agents and bortezomib have 
revolutionized therapy and improved overall survival. However, despite these advances, 
MM remains largely incurable as disease relapse is inevitable. Therefore, there is an urgent 
need for new, tolerable agents that demonstrate the ability to either overcome or prevent 
drug resistance. The role of the SUMOylation pathway in Multiple Myeloma is only 
beginning to be understood and appears to be a novel therapeutic target that can be used 
not only to treat MM but also to overcome drug resistance. Future studies will address the 
role of this emerging pathway in myelomagenesis. 
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